Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CytoMed Therapeutics Limited ( (GDTC) ) just unveiled an update.
On October 2, 2025, CytoMed Therapeutics Limited announced a significant advancement in their research collaboration with The University of Texas, MD Anderson Cancer Center. The publication of their preclinical study highlights the potential of CytoMed’s allogeneic γδ T cell therapy for treating acute myeloid leukemia (AML), marking a promising step forward in developing ‘off-the-shelf’ immunotherapy solutions. This development is expected to pave the way for further clinical trials in Southeast Asia, potentially offering new treatment options for patients with limited alternatives, thereby strengthening CytoMed’s position in the biopharmaceutical industry.
Spark’s Take on GDTC Stock
According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.
CytoMed Therapeutics Limited is facing significant financial challenges, with substantial declines in revenue and persistent losses. The technical indicators suggest a bearish trend with potential short-term opportunities due to oversold conditions. Valuation metrics, including a negative P/E ratio, reflect poor profitability and lack of dividend yield. These factors contribute to a low overall stock score, highlighting the need for improved financial strategies and market conditions to enhance investor confidence.
To see Spark’s full report on GDTC stock, click here.
More about CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a Singapore-based clinical stage biopharmaceutical company that focuses on developing novel, affordable donor-derived cell-based immunotherapies for treating a wide range of cancers, including both blood and solid tumors. The company was incorporated in 2018 and spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency. CytoMed leverages its proprietary technologies, such as gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create allogeneic immunotherapies inspired by the clinical success of CAR-T therapies.
Average Trading Volume: 13,953
Technical Sentiment Signal: Sell
Current Market Cap: $23.58M
For an in-depth examination of GDTC stock, go to TipRanks’ Overview page.